Introduction {#tca12929-sec-0005}
============

Remarkable progress has been made in the treatment of lung cancer in recent years. Blockade of immune checkpoints with monoclonal antibodies has recently emerged as a new therapeutic tool for lung cancer.[1](#tca12929-bib-0001){ref-type="ref"}, [2](#tca12929-bib-0002){ref-type="ref"}, [3](#tca12929-bib-0003){ref-type="ref"}, [4](#tca12929-bib-0004){ref-type="ref"}, [5](#tca12929-bib-0005){ref-type="ref"} Immune responses are fine‐tuned and regulated through a combination of stimulatory and inhibitory molecules and signal pathways. PD‐L1 binds PD‐1 as counter receptors to offer signals that control and suppress cytotoxic T lymphocyte responses in both autoimmune responses and evasion of tumor immunity.[6](#tca12929-bib-0006){ref-type="ref"} Consequently, clinical trials of blocking monoclonal antibodies (mAbs) against PD‐1 and PD‐L1 in a variety of solid tumors have shown promising results and have validated this pathway as a therapeutic target. The KEYNOTE‐024 clinical trial demonstrated that pembrolizumab, an anti‐PD‐1 immune checkpoint inhibitor, is associated with longer progression‐free and overall survival (OS) than platinum‐based chemotherapy in advanced non‐small cell lung cancer (NSCLC) patients with a PD‐L1 tumor proportion score (TPS) of ≥ 50%.[7](#tca12929-bib-0007){ref-type="ref"}, [8](#tca12929-bib-0008){ref-type="ref"} Therefore, evaluation of the relationship between clinicopathological characteristics and a PD‐L1 TPS ≥ 50% might provide valuable information to predict benefit for patients receiving first‐line immunotherapy.

Although the association between PD‐L1 expression and clinicopathological characteristics in NSCLC has already been examined, the relationship between oncogenic driver mutations, smoking history, and PD‐L1 expression status remains unclear. Recent studies have demonstrated that high PD‐L1expression is more frequently found in resected NSCLC patients with a smoking history,[9](#tca12929-bib-0009){ref-type="ref"}, [10](#tca12929-bib-0010){ref-type="ref"}, [11](#tca12929-bib-0011){ref-type="ref"} while other studies have found no relationship.[12](#tca12929-bib-0012){ref-type="ref"} Furthermore, detailed analysis of the association between PD‐L1 expression and smoking variables was not performed in these studies. Several studies have revealed that the level of PD‐L1 expression is significantly higher in patients with *ALK* fusion or *EGFR* mutation, and these driver oncogenic alterations induce PD‐L1 expression by activating downstream signaling pathways in NSCLC.[13](#tca12929-bib-0013){ref-type="ref"} However, other studies have shown conflicting results.[14](#tca12929-bib-0014){ref-type="ref"}, [15](#tca12929-bib-0015){ref-type="ref"} Therefore, precise analysis of PD‐L1 expression and correlations with oncogenic driver mutations and smoking is still worthwhile. In this study, we assessed PD‐L1 expression in surgically resected NSCLC patients by SP263 monoclonal antibody and analyzed the correlations of PD‐L1 expression with cigarette smoking, driver oncogenic alterations, and patient outcomes using a cutoff value of 50% PD‐L1 TPS.

Methods {#tca12929-sec-0006}
=======

Patients and samples {#tca12929-sec-0007}
--------------------

We retrospectively screened 241 NSCLC patients who underwent surgery at the Cancer Hospital, Chinese Academy of Medical Sciences (CAMS, Beijing, China) between June 2012 and April 2013. Clinicopathological features, including age, gender, smoking history, histology, pathologic tumor node metastasis (TNM) stage (the American Joint Committee on Cancer 8th edition Lung Cancer Staging system), and *EGFR* and *KRAS* mutation status were studied. In addition, detailed assessments of smoking variables were also analyzed, including the average number of cigarettes smoked per day, total smoking duration, and cumulative pack‐years. After surgery, routine examinations, including chest computed tomography and blood tests (including serum tumor markers), were performed at three‐month intervals for the first three years and at six‐month intervals thereafter. The Ethics Committee of the Cancer Hospital, CAMS, approved this study protocol and all patients provided written informed consent prior to study commencement.

Immunohistochemical analysis of PD‐L1 {#tca12929-sec-0008}
-------------------------------------

Immunohistochemistry (IHC) was conducted using a fully automated Ventana Benchmark XT stainer with the pre‐diluted Ventana PD‐L1 Rabbit monoclonal primary antibody (SP263, CAT No. 740‐4907; Ventana Medical Systems, Roche Group, Tuscon, AZ, USA). Tumor cells showing membranous staining for PD‐L1 were evaluated as positive cells. The TPS was used to evaluate PD‐L1 expression, which was the percentage of PD‐L1 positive tumor cells showing partial or complete membrane staining in the overall tumor sections. We classified PD‐L1 expression into three levels: PD‐L1 TPS ≥ 50%, PD‐L1 TPS 1--49% and PD‐L1 TPS \< 1%. Two experienced observers assessed all immunohistochemical images; if the independent judgments did not agree, the observers reviewed the slides together to achieve consensus.

Detection of *EGFR* and *KRAS* mutations {#tca12929-sec-0009}
----------------------------------------

Mutation detection was carried out as previously described.[16](#tca12929-bib-0016){ref-type="ref"} Briefly, to determine mutation status, four exons that code for the tyrosine kinase domain of the *EGFR* gene (exons 18--21) and two exons of the *KRAS* gene (codons 12, 13) were examined.

Statistical analysis {#tca12929-sec-0010}
--------------------

The relationship between PD‐L1 expression and clinicopathologic variables was evaluated statistically by Pearson\'s χ^2^ or Fisher\'s exact test as appropriate. Multivariable analysis was performed using a logistic regression model to investigate the association between PD‐L1 expression and patient characteristics. Disease‐free survival (DFS) was considered as the period between surgery and the date of the recurrence, and OS as the period between surgery and the date of the last follow‐up or death. These rates were estimated using the Kaplan--Meier method with the log rank test. Cox proportional hazards regression analysis was performed to assess the hazard ratios for positive risk factors. Statistical tests were two‐sided, and the significance level for all analyses was set at *P* \< 0.05. Statistics were calculated using SPSS version 20.0 (IBM Corp., Armonk, NY, USA).

Results {#tca12929-sec-0011}
=======

Patient characteristics {#tca12929-sec-0012}
-----------------------

The clinicopathologic characteristics of patients, driver mutation status, and PD‐L1 TPS are reported in Table [1](#tca12929-tbl-0001){ref-type="table"}. The majority of patients were female (56.0%) and never smokers (60.2%). Almost all patients had a diagnosis of adenocarcinoma (95.0%). *KRAS* mutations were detected in 23 out of 241 patients (9.5%) and *EGFR* mutations in 79: 36 patients with a deletion in exon 19, 37 with an L858R mutation in exon 21, and 6 patients with other mutations. A PD‐L1 TPS ≥ 50% was observed in 35 cases (14.5%), a PD‐L1 TPS 1--49% in 53 cases (22.0%), and a PD‐L1 TPS \< 1% in 153 cases (63.5%) (Fig [1](#tca12929-fig-0001){ref-type="fig"}).

###### 

Patient characteristics, driver mutation status, and PD‐L1 TPS

  Characteristics                                 No. of patients
  ----------------------------------------------- -----------------
  Gender                                          
  Male                                            106 (44.0%)
  Female                                          135 (56.0%)
  Age (years)                                     
  Median                                          56
  Range                                           24--77
  Smoking history                                 
  Never                                           145 (60.2%)
  Current/former                                  96 (39.8%)
  Histology                                       
  Adenocarcinoma                                  229 (95.0%)
  Squamous cell carcinoma                         8 (3.3%)
  Adenosquamous carcinoma                         4 (1.7%)
  p stage                                         
  IA                                              40 (16.6%)
  IB                                              46 (19.1%)
  IIA                                             3 (1.2%)
  IIB                                             39 (16.2%)
  IIIA                                            91 (37.8%)
  IIIB                                            22 (9.1%)
  *EGFR* status                                   
  Wild‐type                                       162 (67.2%)
  Exon 19 deletion                                36 (14.9%)
  Exon 21 L858R                                   37 (15.4%)
  Others[†](#tca12929-note-0002){ref-type="fn"}   6 (2.5%)
  *KRAS* status                                   
  Wild‐type                                       218 (90.5%)
  Mutated                                         23 (9.5%)
  PD‐L1 TPS                                       
  \< 1%                                           153 (63.5%)
  1--49%                                          53 (22.0%)
  ≥ 50%                                           35 (14.5%)

Others: exon 18, S768I and insertion, exon 21 L861Q, complex mutation with exon 19 deletion + T790M.

TPS, tumor proportion score.

![PD‐L1 tumor proportion score (TPS) immunohistochemistry (IHC) results in non‐small cell lung cancer patients using a SP263 antibody on a fully automated Ventana Benchmark XT stainer. (**a**) Negative staining for PD‐L1; (**b**) PD‐L1 TPS of 1--10%; (**c**) PD‐L1 TPS of 11--49%; (**d**) PD‐L1 TPS of ≥ 50%.](TCA-10-175-g002){#tca12929-fig-0001}

Association between PD‐L1 expression and clinicopathological characteristics {#tca12929-sec-0013}
----------------------------------------------------------------------------

The association between a PD‐L1 TPS ≥ 50% and clinicopathological characteristics was examined by Pearson\'s χ^2^ or Fisher\'s exact test (Table [S1](#tca12929-supitem-0001){ref-type="supplementary-material"}). A PD‐L1 TPS ≥ 50% was significantly associated with smoking (*P* \< 0.001) and wild type *EGFR* (*P* = 0.012). No significant association was found between a PD‐L1 ≥ 50% and gender (male vs. female, *P* = 0.885), age (\> 56 vs. ≤ 56 years, *P* = 0.060), histology (adenocarcinoma vs. non‐adenocarcinoma, *P* = 1.000), pathologic tumor stage (I or II vs. III, *P* = 0.880), or *KRAS* status (wild‐type vs. mutated, *P* = 0.054). Multivariate analysis by logistic regression also revealed that a PD‐L1 TPS ≥ 50% was significantly associated with smoking (*P* \< 0.001) and wild type *EGFR* status (*P* = 0.032) (Table [S2](#tca12929-supitem-0001){ref-type="supplementary-material"}). The relationship between a PD‐L1 TPS ≥ 50% and smoking variables, including average number of cigarettes smoked per day, total smoking duration, and cumulative pack‐years was assessed in smokers. Positive associations were observed between a PD‐L1 TPS ≥ 50% and total smoking duration (*P* = 0.001) (Table [S3](#tca12929-supitem-0001){ref-type="supplementary-material"}).

Univariate and multivariate survival analyses in non‐small cell lung cancer patients {#tca12929-sec-0014}
------------------------------------------------------------------------------------

The median follow‐up time for all 241 patients was 30 months (range: 3--66 months). NSCLC patients with a PD‐L1 TPS ≥ 50% had significantly shorter DFS and OS compared to those with a PD‐L1 TPS \< 50% (*P* = 0.001 and *P* \< 0.001, respectively) (Figs [2](#tca12929-fig-0002){ref-type="fig"}, [3](#tca12929-fig-0003){ref-type="fig"}).

![Kaplan--Meier analysis of disease‐free survival according to a PD‐L1 tumor proportion score (TPS) of \< 50% or ≥ 50% in non‐small cell lung cancer patients.](TCA-10-175-g003){#tca12929-fig-0002}

![Kaplan--Meier analysis of overall survival according to a PD‐L1 tumor proportion score (TPS) of \< 50% or ≥ 50% in non‐small cell lung cancer patients.](TCA-10-175-g001){#tca12929-fig-0003}

Cox proportional hazards regression models showed that male gender, smoking, advanced stage, wild‐type *EGFR*, *KRAS* mutation, and a PD‐L1 TPS ≥ 50% were associated with significantly shorter OS (*P* = 0.036, *P* = 0.009, *P* \< 0 0.001, *P* \< 0 0.001, *P* \< 0 0.001, and *P* \< 0.001, respectively). In multivariate analysis, advanced stage, wild‐type *EGFR*, *KRAS* mutation, and a PD‐L1 TPS ≥ 50% remained predictors of OS (*P* \< 0.001, *P* = 0.026, *P* = 0.040, and *P* \< 0.001, respectively). Cox proportional hazards regression models showed that male gender, smoking, advanced stage, and a PD‐L1 TPS ≥ 50% were associated with significantly shorter DFS (*P* = 0.011, *P* = 0.010, *P* \< 0.001, and *P* = 0.001, respectively), and advanced stage and a PD‐L1 TPS ≥ 50% remained predictors of DFS in multivariate analysis (*P* \< 0.001 and *P* \< 0.001, respectively) (Table [2](#tca12929-tbl-0002){ref-type="table"}).

###### 

Univariate and multivariate analyses of DFS and OS in all patients

                                     DFS         OS                                                                                                                       
  -------------------- ------------- ----------- ------------ ---------- ----------- ------------ ---------- ----------- ------------ ---------- ----------- ------------ ----------
  Gender                                                                                                                                                                  
  Male                 106 (44.0%)   1.0 (ref)                           1.0 (ref)                           1.0 (ref)                           1.0 (ref)                
  Female               135 (56.0%)   0.64        0.46--0.90   0.011      0.79        0.51--1.23   0.300      0.62        0.40--0.97   0.036      0.77        0.45--1.34   0.361
  Age (years)                                                                                                                                                             
  ≤ 56                 118 (49.0%)   1.0 (ref)                                                               1.0 (ref)                                                    
  \> 56                123 (51.0%)   0.97        0.69--1.37   0.871                                          1.02        0.65--1.58   0.946                               
  Smoking history                                                                                                                                                         
  Never                145 (60.2%)   1.0 (ref)                           1.0 (ref)                           1.0 (ref)                           1.0 (ref)                
  Current/former       96 (39.8%)    1.57        1.12--2.22   0.010      1.00        0.62--1.62   0.994      1.81        1.16--2.81   0.009      0.87        0.48--1.57   0.635
  Histology                                                                                                                                                               
  Adenocarcinoma       229 (95.0%)   1.0 (ref)                                                               1.0 (ref)                                                    
  Non‐Adenocarcinoma   12 (5.0%)     1.41        0.66--3.03   0.373                                          1.84        0.80--4.23   0.152                               
  p stage                                                                                                                                                                 
  I/II                 128 (35.7%)   1.0 (ref)                           1.0 (ref)                           1.0 (ref)                           1.0 (ref)                
  III                  113 (64.3%)   3.87        2.67--5.61   \< 0.001   3.87        2.66--5.64   \< 0.001   2.87        1.79--4.62   \< 0.001   2.72        1.68--4.42   \< 0.001
  *EGFR* status                                                                                                                                                           
  Wild‐type            162 (67.2%)   1.0 (ref)                                                               1.0 (ref)                           1.0 (ref)                
  Mutated              79 (32.8%)    0.70        0.48--1.02   0.065                                          0.53        0.31--0.92   \< 0.001   0.48        0.25--0.91   0.026
  *KRAS* status                                                                                                                                                           
  Wild‐type            218 (90.5%)   1.0 (ref)                                                               1.0 (ref)                           1.0 (ref)                
  Mutated              23 (9.5%)     1.54        0.90--2.65   0.114                                          2.66        1.35--5.21   \< 0.001   1.88        1.03--3.43   0.040
  PD‐L1 status                                                                                                                                                            
  \< 50%               206 (85.5%)   1.0 (ref)                           1.0 (ref)                           1.0 (ref)                           1.0 (ref)                
  ≥ 50%                35 (14.5%)    2.13        1.39--3.26   0.001      2.55        1.56--4.18   \< 0.001   2.37        1.24--4.54   \< 0.001   3.07        1.73--5.45   \< 0.001

DFS, disease‐free survival; OS, overall survival; HR, hazard ratio; ref., reference category; TPS, tumor proportion score.

Discussion {#tca12929-sec-0015}
==========

During the past few years, immune checkpoint therapies have established a new era for the treatment of patients beyond tumor types, yet the predictors of response remain largely undetermined. Although several studies have evaluated PD‐L1 expression in NSCLC, the clinicopathologic characteristics and molecular features associated with a PD‐L1 TPS ≥ 50% remain controversial. Herein, we evaluated PD‐L1 expression by IHC in 241 surgically resected NSCLC specimens and examined correlations between PD‐L1 expression and smoking history and oncogenic driver mutations. Our data revealed that 14.5% of NSCLC patients had a PD‐L1 TPS ≥ 50%, as measured via SP263 assay. A PD‐L1 TPS of ≥ 50% was significantly higher in smokers and *EGFR* wild‐type patients. Univariate and multivariate survival analysis revealed that patients with a PD‐L1 TPS ≥ 50% had poorer DFS and OS than those with a PD‐L1 TPS \< 50%.

Carcinogens in tobacco are known to be responsible for direct DNA damage and mutagenesis in NSCLC.[17](#tca12929-bib-0017){ref-type="ref"} Smoking‐related lung cancers are characterized by a greater mutation burden than lung cancers occurring in never smokers.[18](#tca12929-bib-0018){ref-type="ref"}, [19](#tca12929-bib-0019){ref-type="ref"} Tumors with a greater number of somatic mutations generate more immunogenic neoantigens, which can drive immune responses, and the levels of neoantigens may correlate with the degree of immune response.[20](#tca12929-bib-0020){ref-type="ref"}, [21](#tca12929-bib-0021){ref-type="ref"} Studies based on The Cancer Genome Atlas project showed that NSCLC patients with a larger number of somatic mutations are more sensitive to immunotherapy with PD‐1/PD‐L1 inhibitors.[22](#tca12929-bib-0022){ref-type="ref"} Moreover, patients with high PD‐L1 expression show greater sensitivity to anti‐PD‐1/PD‐L1 inhibitors.[3](#tca12929-bib-0003){ref-type="ref"}, [5](#tca12929-bib-0005){ref-type="ref"} Therefore, tumors with excessive somatic mutation burdens tend to be associated with high PD‐L1 expression. Consistent with this data, our results revealed that smokers more frequently had a PD‐L1 TPS ≥ 50% compared to non‐smokers. In addition, persistent exposure to smoking increases the risk of chronic inflammation, which plays a vital role in the regulation of PD‐L1 expression by the interferon‐γ (IFN‐γ) driven inflammatory signaling pathway.[23](#tca12929-bib-0023){ref-type="ref"} IFN‐γ is a proinflammatory cytokine that is abundantly produced by T cells upon activation; binding of IFN‐γ to its receptor on tumor cells results in activation of the classic JAK‐STAT signaling pathway, inducing increased PD‐L1 expression.[24](#tca12929-bib-0024){ref-type="ref"} Furthermore, we performed a detailed analysis of the association between smoking variables and a PD‐L1 TPS ≥ 50%. Our data showed that tumors with a PD‐L1 TPS of ≥ 50% were more common in patients with a total smoking duration \> 20 years than in those who smoked an average of \> 20 cigarettes per day or cumulative pack‐years \> 20. Our results suggest that total smoking duration is more predictive of a PD‐L1 TPS ≥ 50% than the average number of cigarettes smoked per day or cumulative pack‐years.

PD‐L1 expression was recently found to be elevated in NSCLC patients harboring *EGFR* mutations.[12](#tca12929-bib-0012){ref-type="ref"}, [25](#tca12929-bib-0025){ref-type="ref"} Several in vitro studies have shown that *EGFR* mutation induces PD‐L1 expression via downstream pathways mediated by MEK‐ERK, PI3K‐AKT, or STAT3 signaling pathways.[26](#tca12929-bib-0026){ref-type="ref"} However, in the present study, a PD‐L1 TPS of ≥ 50% was more frequently observed in patients with negative driver oncogenic alterations in *EGFR*, while most patients harboring *EGFR* mutations had a PD‐L1 TPS of \< 50%. In patients with a PD‐L1 TPS ≥ 50%, subgroup analyses revealed that the majority of patients with wild‐type *EGFR* were smokers (24/30, 80%). Existing evidence shows that *EGFR* mutations are common in non‐smokers, who are likely to have low mutation burdens and inactive inflammatory signaling. Consequently, high mutation burdens and activation of the inflammatory signaling pathway as a result of smoking tend to have a greater influence on PD‐L1 expression compared to activation of the downstream signaling pathway induced by *EGFR* mutation. Thus, smokers are more likely to have high PD‐L1 expression than non‐smokers with *EGFR* mutation.

Recent studies have evaluated the prognostic effect of PD‐L1 expression in NSCLC.[27](#tca12929-bib-0027){ref-type="ref"}, [28](#tca12929-bib-0028){ref-type="ref"}, [29](#tca12929-bib-0029){ref-type="ref"} However, the prognostic relevance of PD‐L1 expression in NSCLC remains controversial. In our study, univariate and multivariate survival analysis showed that patients with a PD‐L1 TPS ≥ 50% showed significantly poorer DFS and OS compared to those with a PD‐L1 TPS \< 50%. Immune evasion induced by the PD‐1/PD‐L1 pathway plays a significant role in NSCLC. Cancer cells can evade host immune systems by expressing PD‐L1 to downregulate cytotoxic T lymphocytes through inhibitory pathways, which are usually initiated by PD‐1/PD‐L1 interaction. Cancer cells then become uncontrollable in the host immune system, allowing cancer cells to survive and progress.[30](#tca12929-bib-0030){ref-type="ref"} Additionally, our data indicated that patients with *EGFR* mutation were significantly associated with better OS, possibly because these patients have the opportunity to receive EGFR‐tyrosine kinase inhibitors (TKIs). Ota *et al*. demonstrated that EGFR‐TKIs downregulate PD‐L1 expression in *EGFR‐*mutant NSCLC cells but not in those with wild‐type *EGFR*,[31](#tca12929-bib-0031){ref-type="ref"} which indicates that TKIs could not only could induce apoptosis of tumor cells, but also inhibit immune evasion of tumor cells by downregulating PD‐L1 expression. The benefit of TKIs for *EGFR* mutant patients may be partly attributed to the inhibition of tumor cell immune evasion by downregulating the expression of PD‐L1.

There were several limitations to our study. First, it was retrospective and from a single institution; thus, the possibility of bias cannot be excluded. Second, PD‐L1 expression in tumor cells was only evaluated with an SP263 antibody. A large prospective study of clinicopathological characteristics, molecular features, and prognosis of tumors with evaluated PD‐L1 expression with various antibodies is needed to validate this exploratory result.

In conclusion, our results demonstrate that a PD‐L1 TPS of ≥ 50% is associated with poor DFS and OS in NSCLC patients. Furthermore, current smokers without *EGFR* mutations, particularly long‐term smokers, were associated with a PD‐L1 TPS ≥ 50%, which indicates that these NSCLC patients may benefit from immunotherapy.
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**Table S1.** Patient characteristics and PD‐L1 expression status.

**Table S2.** Multivariate analysis of the relationship between a PD‐L1 tumor proportion score (TPS) of ≥ 50% and patient characteristics.

**Table S3.** Associations between cigarette smoking and PD‐L1 expression.
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